[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:  10.3322/caac.21660
[2] 健康中国行动推进委员会. 健康中国行动(2019−2030年)[EB/OL].(2019-07-15)[2023-05-26]. https://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
[3] ZENG H M, CHEN W Q, ZHENG R S, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. doi:  10.1016/S2214-109X(18)30127-X
[4] 中国临床肿瘤学会. 非小细胞肺癌诊疗指南(2021)[M]. 北京: 人民卫生出版社, 2021.
[5] 屠文莲, 董兰岚, 闵秋霞, 等. 奥希替尼在真实世界中治疗EGFR基因突变阳性NSCLC患者的临床疗效及安全性研究[J]. 中国医院用药评价与分析, 2022, 22(9): 1068-1071.
[6] WANG M, ZHU L J, YANG X X, et al. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer[J]. Front Pharmacol, 2023, 14: 1132158. doi:  10.3389/fphar.2023.1132158
[7] 刘建迪, 姚明, 沈颖, 等. 基于DRG的专科标准化平均住院日[J]. 中国医院管理, 2022, 42(10): 48-50. doi:  10.11950/j.issn.1001-5329.2022.10.zgyygl202210012
[8] 陈力, 赵郁馨, 刘国祥, 等. 天津市医疗费用研究[J]. 中国卫生经济, 2008, 27(10): 12-16. doi:  10.3969/j.issn.1003-0743.2008.10.003
[9] WHO. ATC/DDD Index 2023[EB/OL]. （2023-05-27）[2023-06-30]. https://www.whocc.no/atc_ddd_index.

WHO. ATC/DDD Index 2023[EB/OL]. (2023-05-27)[2023-06-30]. https://www.whocc.no/atc_ddd_index.
[10] 刘宇, 陈庆宪, 张福军. 2013—2015年重庆地区39家医院阿片类止痛药利用分析[J]. 中国医院药学杂志, 2018, 38(5): 533-537.
[11] CAI L L, TAO T T, LI H T, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study[J]. J Glob Health, 2022, 12: 11016. doi:  10.7189/jogh.12.11016
[12] ZHENG R S, ZHANG S W, ZENG H M, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. doi:  10.1016/j.jncc.2022.02.002
[13] 韩群啸, 鲍国林, 刘义庆. 肺癌早期诊断研究进展[J]. 中国医药, 2023, 18(5): 761-764.
[14] WANG M N, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med, 2021, 27(8): 1345-1356. doi:  10.1038/s41591-021-01450-2
[15] YANG Y, ZHANG Y C, WAGNER A K, et al. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: a cohort study based on national health insurance data[J]. J Glob Health, 2023, 13: 04083. doi:  10.7189/jogh.13.04083
[16] YI H B, SHI F H, WANG Z H, et al. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis[J]. BMJ Open, 2023, 13(10): e064811. doi:  10.1136/bmjopen-2022-064811
[17] ZHANG Y C, WUSHOUER H, HAN S, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China[J]. BMJ Glob Health, 2021, 6(7): e006196. doi:  10.1136/bmjgh-2021-006196
[18] AYATI A, MOGHIMI S, SALARINEJAD S, et al. A review on progression of epidermal growth factor receptor(EGFR)inhibitors as an efficient approach in cancer targeted therapy[J]. Bioorg Chem, 2020, 99: 103811. doi:  10.1016/j.bioorg.2020.103811
[19] MIYAUCHI E, MORITA S, NAKAMURA A, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. J Clin Oncol, 2022, 40(31): 3587-3592. doi:  10.1200/JCO.21.02911
[20] SOLOMON B J, BAUER T M, MOK T S K, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. Lancet Respir Med, 2023, 11(4): 354-366. doi:  10.1016/S2213-2600(22)00437-4
[21] ANDO K, MANABE R, KISHINO Y, et al. Comparative efficacy of ALK inhibitors for treatment-Naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis[J]. Int J Mol Sci, 2023, 24(3): 2242. doi:  10.3390/ijms24032242
[22] 孟新源, 张莉, 薛淑萍. EGFR突变晚期NSCLC患者第1、2代EGFR-TKI治疗耐药后序贯奥希替尼或阿美替尼治疗的效果观察[J]. 中国医院用药评价与分析, 2023, 23(9): 1079-1081.